{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:17:02Z","timestamp":1793902622704,"version":"4.8.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with HER2-positive breast cancer (HER2\u2005+\u2005BC) develop central nervous system metastases twice as often as patients with luminal HER2-negative breast cancer. Leptomeningeal progression results in a drastically altered prognosis with limited therapeutic options. This phase II study was conducted to assess the efficacy of intrathecal (IT) trastuzumab in HER2\u2005+\u2005BC patients with leptomeningeal metastasis (LM), based on a phase I dose-escalation study that had determined the recommended weekly dose of 150 mg for phase II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients received weekly administrations of 150 mg of IT trastuzumab. The primary endpoint was clinical neurologic progression-free survival (LM-related-PFS) after 8 weeks. Overall survival (OS), toxicities, and quality of life (QoL) were secondary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 19 enrolled patients, 16 (84%) had concomitant brain metastases, 15 of them had received prior radiotherapy to the brain. All patients had received at least one line of systemic anti-HER2 therapy. After 8 weeks, 14 patients (74%) were free of neurological progression. The median LM-related-PFS was 5.9 months and the median OS was 7.9 months. According to the QLQ-C30 and BN20 scales, the global health-related QoL status seemed preserved and no toxicity above grade 3 was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Conducting studies on patients with LM poses significant challenges and ethical dilemmas inherent to this population. Despite some limits, this phase II study\u2019s findings in terms of clinical neurologic response and QoL\u2019s control confirms weekly administration of 150 mg of IT trastuzumab as a valuable option for HER\u2005+\u2005BC patients with LM and support the interest for further investigations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noac180","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T19:48:56Z","timestamp":1658519336000},"page":"365-374","source":"Crossref","is-referenced-by-count":61,"title":["Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9815-6358","authenticated-orcid":false,"given":"Florence","family":"Oberkampf","sequence":"first","affiliation":[{"name":"Department of Oncology, Institut Curie-St Cloud , 92210, Saint Cloud , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Curie-St Cloud , 92210, Saint Cloud , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfa","family":"Trabelsi Grati","sequence":"additional","affiliation":[{"name":"Department of Genetics, Institut Curie-Paris \u00a0 , 75005, Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9milie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Neurosurgery Department, University of Lille \u00a0 France , CHU Lille , France"},{"name":"Neurology, Department of Medical Oncology, Centre Oscar Lambret , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tr\u00e9dan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Leon Berard , 69008, Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Turbiez","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Institut Curie-St Cloud , 92210, Saint Cloud , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kadi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institut Curie-St Cloud , 92210, Saint Cloud , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coraline","family":"Dubot","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Curie-St Cloud , 92210, Saint Cloud , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Taillibert","sequence":"additional","affiliation":[{"name":"Department of Neurology Mazarin, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re , 75013, Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vacher","sequence":"additional","affiliation":[{"name":"Department of Genetics, Institut Curie-Paris \u00a0 , 75005, Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6251-286X","authenticated-orcid":false,"given":"Claire","family":"Bonneau","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institut Curie-St Cloud , 92210, Saint Cloud , France"},{"name":"INSERM U900, Institut Curie-St Cloud , Saint Cloud , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"2023070713231887000_CIT0001","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"Eur J Cancer."},{"key":"2023070713231887000_CIT0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2019.11.001","article-title":"Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort","volume":"125","author":"Pasquier","year":"2020","journal-title":"Eur J Cancer."},{"issue":"20","key":"2023070713231887000_CIT0003","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023070713231887000_CIT0004","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer."},{"issue":"14","key":"2023070713231887000_CIT0005","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol."},{"issue":"4","key":"2023070713231887000_CIT0006","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.18632\/oncotarget.5911","article-title":"Leptomeningeal metastasis in breast cancer\u2014a systematic review","volume":"7","author":"Scott","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2023070713231887000_CIT0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast cancer leptomeningeal metastasis\u2014the role of multimodality treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"J Neurooncol."},{"issue":"4","key":"2023070713231887000_CIT0008","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun","year":"2020","journal-title":"Neuro Oncol"},{"issue":"7","key":"2023070713231887000_CIT0009","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"202","journal-title":"Neuro Oncol"},{"issue":"1","key":"2023070713231887000_CIT0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs."},{"issue":"11","key":"2023070713231887000_CIT0011","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/annonc\/mdi371","article-title":"Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy","volume":"16","author":"Burstein","year":"2005","journal-title":"Ann Oncol."},{"issue":"11","key":"2023070713231887000_CIT0012","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med."},{"key":"2023070713231887000_CIT0013","doi-asserted-by":"crossref","first-page":"102046","DOI":"10.1016\/j.ctrv.2020.102046","article-title":"Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression","volume":"88","author":"Zagouri","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"2023070713231887000_CIT0014","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"EORTC Quality of Life Group, Quality of Life Unit. Quality of life research within the EORTC\u2014the EORTC QLQ-C30","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer."},{"issue":"5","key":"2023070713231887000_CIT0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"key":"2023070713231887000_CIT0016","author":"National Cancer Institute, U.S. Department of Health and Human Services.","year":"2010"},{"issue":"11","key":"2023070713231887000_CIT0017","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer."},{"issue":"9","key":"2023070713231887000_CIT0018","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdq726","article-title":"Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients","volume":"22","author":"Maringwa","year":"2011","journal-title":"Ann Oncol."},{"key":"2023070713231887000_CIT0019","doi-asserted-by":"crossref","first-page":"379123","DOI":"10.1155\/2011\/379123","article-title":"Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity","volume":"2011","author":"Alderson","year":"2011","journal-title":"J Biomed Biotechnol."},{"key":"2023070713231887000_CIT0020","author":"Scott","year":"2008"},{"issue":"suppl_4","key":"2023070713231887000_CIT0021","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"2023070713231887000_CIT0022","author":"Northwestern University.","year":"2019"},{"key":"2023070713231887000_CIT0023","doi-asserted-by":"crossref","first-page":"v19","DOI":"10.1093\/neuonc\/nou237.46","article-title":"AT-47 Phase I trial of intrathecal trastuzumab in HER2 positive leptomeningeal metastases","volume":"16","author":"Raizer","year":"2014","journal-title":"Neuro Oncol"},{"issue":"4","key":"2023070713231887000_CIT0024","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"2023070713231887000_CIT0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoncol.2016.4884","article-title":"Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2\/HER2\u2013positive breast cancer","volume":"3","author":"Gavin","year":"2017","journal-title":"JAMA Oncol."},{"key":"2023070713231887000_CIT0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-1","article-title":"A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer","volume":"6","author":"Mellor","year":"2013","journal-title":"J Hematol Oncol."},{"issue":"11","key":"2023070713231887000_CIT0027","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023070713231887000_CIT0028","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.2188","article-title":"Antigen mass may influence trastuzumab concentrations in cerebrospinal fluid after intrathecal administration","volume":"110","author":"Le Tilly","year":"2021","journal-title":"Clin Pharmacol Ther."},{"issue":"4","key":"2023070713231887000_CIT0029","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Shapiro","year":"1975","journal-title":"N Engl J Med."},{"issue":"8","key":"2023070713231887000_CIT0030","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/cncr.24921","article-title":"Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis","volume":"116","author":"Glantz","year":"2010","journal-title":"Cancer."},{"issue":"27","key":"2023070713231887000_CIT0031","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol."},{"issue":"7","key":"2023070713231887000_CIT0032","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med."},{"issue":"23","key":"2023070713231887000_CIT0033","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol."},{"issue":"7","key":"2023070713231887000_CIT0034","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med."},{"issue":"5","key":"2023070713231887000_CIT0035","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac180\/45951846\/noac180.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/2\/365\/50838002\/noac180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/2\/365\/50838002\/noac180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T09:25:51Z","timestamp":1688721951000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/2\/365\/6648801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,22]]},"published-print":{"date-parts":[[2023,2,14]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac180","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,7,22]]}}}